Short answer
Personalis, Inc. (PSNL) filed an 8-K current report with the SEC on August 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q2 FY2026 results cover the quarter ended June 30, 2026.
Personalis, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 FY2026 results cover the quarter ended June 30, 2026
- Full financial results and management commentary furnished in Exhibit 99.1
- Disclosure furnished under Item 2.02, limiting Section 18 Exchange Act liability
Item EX-99.1 · Exhibit EX-99.1
- Q2 revenue $22.4M, up 30% YoY, led by pharma testing services rising 51% to $16.8M
- Clinical revenue surged 442% to $2.6M as testing volume reached 10,384, up 199% YoY
- Medicare coverage expanded NeXT Personal to four indications, supporting further clinical adoption and reimbursement growth
- Operating loss widened to $33.6M from $21.8M, while net loss increased to $31.7M from $20.1M
- Cash, equivalents and short-term investments totaled approximately $212.7M; merger with Tempus means guidance is withdrawn
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Personalis, Inc. 8-K filings
Get the next PSNL 8-K as it lands
Follow PSNL for push alerts, or ask the research agent what this filing means.